US 11,693,009 B2
Methods for detecting post-infectious irritable bowel syndrome
Mark Pimentel, Los Angeles, CA (US); and Christopher Chang, Los Angeles, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed by Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed on May 18, 2020, as Appl. No. 16/877,230.
Application 16/877,230 is a continuation in part of application No. 16/734,842, filed on Jan. 6, 2020, abandoned.
Application 16/734,842 is a continuation in part of application No. 16/594,935, filed on Oct. 7, 2019, abandoned.
Application 16/734,842 is a continuation of application No. 16/185,955, filed on Nov. 9, 2018, granted, now 10,527,621, issued on Jan. 7, 2020.
Application 16/734,842 is a continuation of application No. 16/877,230.
Application 16/877,230 is a continuation in part of application No. 16/152,806, filed on Oct. 5, 2018, granted, now 10,690,679.
Application 16/594,935 is a continuation of application No. 15/922,604, filed on Mar. 15, 2018, granted, now 10,466,254, issued on Nov. 5, 2019.
Application 16/185,955 is a continuation of application No. 15/855,792, filed on Dec. 27, 2017, granted, now 10,151,752, issued on Dec. 11, 2018.
Application 15/922,604 is a continuation of application No. 15/609,959, filed on May 31, 2017, granted, now 9,952,223, issued on Apr. 24, 2018.
Application 16/152,806 is a continuation of application No. 14/878,416, filed on Oct. 8, 2015, granted, now 10,132,814, issued on Nov. 20, 2018.
Application 15/855,792 is a continuation of application No. 14/793,523, filed on Jul. 7, 2015, granted, now 9,869,676, issued on Jan. 16, 2018.
Application 15/609,959 is a continuation of application No. 14/428,195, granted, now 9,702,884, issued on Jul. 11, 2017, previously published as PCT/US2013/055626, filed on Aug. 19, 2013.
Application 14/793,523 is a continuation of application No. 13/148,252, granted, now 9,110,081, issued on Aug. 18, 2015, previously published as PCT/US2010/023911, filed on Feb. 11, 2010.
Claims priority of provisional application 62/085,825, filed on Dec. 1, 2014.
Claims priority of provisional application 62/061,877, filed on Oct. 9, 2014.
Claims priority of provisional application 61/762,632, filed on Feb. 8, 2013.
Claims priority of provisional application 61/701,923, filed on Sep. 17, 2012.
Claims priority of provisional application 61/286,250, filed on Dec. 14, 2009.
Claims priority of provisional application 61/151,779, filed on Feb. 11, 2009.
Prior Publication US 2020/0284804 A1, Sep. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01)
CPC G01N 33/6854 (2013.01) [G01N 2333/205 (2013.01); G01N 2800/065 (2013.01); G01N 2800/52 (2013.01)] 18 Claims
 
1. A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof, comprising:
obtaining a biological sample from a subject having a symptom of post-infectious irritable bowel syndrome (PI-IBS);
detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof in an enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, flow cytometry, a radioimmuno assay, or affinity purification, by contacting CDT, CdtA, CdtB, CdtC, or a fragment thereof, to the biological sample and detecting a signal that indicates the presence of the antibody capable of binding to CDT, CdtA, CdtB, CdtC, or a fragment thereof.
 
16. A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof, comprising:
obtaining whole blood, plasma or serum from a subject having a symptom of post-infectious irritable bowel syndrome (PI-IBS);
detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof in an enzyme-linked immunosorbent assay (ELISA) by contacting CdtB of Campylobacter jejuni or a fragment thereof to the whole blood, plasma or serum and detecting a signal that indicates the presence of the antibody capable of binding to CdtB of Campylobacter jejuni or the fragment thereof.